Post by Octant

We're excited to share that our TYK2 deep mutational scanning paper, co-authored with Bristol Myers Squibb scientists, has been published as a Reviewed Preprint in eLife. Peer reviewers highlighted the work as a standout study that delivers new insights into TYK2 biology and drug response. Using Octant's Deep Mutational Scanning (DMS) platform, we profiled >23,000 amino acid variants across all domains of TYK2 for both IFN-α signaling and protein abundance. Integrating these two functional readouts enabled us to build the most comprehensive structure-function map of TYK2 to date. This atlas revealed: - Novel allosteric sites across the protein - Drug resistance and potentiation variants at amino acid resolution for TYK2 inhibitors - Evidence that both common and rare human variants protective against autoimmune disease reduce TYK2 protein abundance, highlighting targeted protein degradation as a promising therapeutic strategy Since datasets like this can continue to generate new insights, we’ve made the full dataset available through MaveDB for the community to explore: https://lnkd.in/gbHWZR3Y Huge congratulations to Octonauts past and present, and our partners at BMS, for driving this work forward. Read the paper here: https://lnkd.in/guv5emkE